| Apellido | BUROTTO PICHUN |
| Nombre | MAURICIO EMANUEL |
| ID | 5016288 |
"Su solicitud se enviará en seg. Por favor espere."
SUGERENCIAS
BUROTTO-PICHUN, Mauricio Autor ID: 1158076 ver autor
Articulos ( 102 en total, se muestran 3 )
●
● <i>STK11</i><i> and</i><i> KEAP1</i> mutations in non-small cell lung cancer patients: Descriptive analysis and prognostic value among Hispanics (STRIKE registry-CLICaP), 2022
● 75 Mg of Erlotinib in Latin American Patients with Metastatic Non-Small Cell Lung Cancer - Long Term Analysis, 2018
Afiliaciones ( 38 en total, se muestran 3 )
● Bradford Hill Centro de Investigacion Clinica
● Bradford Hill Clin Ctr
● Bradford Hill Clin Res Ctr
Burotto P., Mauricio Autor ID: 3900700 ver autor
Articulos ( 1 en total )
● Cáncer pulmonar el peor efecto del tabaquismo, 2017
Afiliaciones ( 1 en total )
● Clínica Alemana de Santiago
Burotto, M. Autor ID: 8267519 ver autor
Articulos ( 1 en total )
● Final analysis of the phase III LITESPARK-005 study of belzutifan versus everolimus in participants (pts) with previously treated advanced clear cell renal cell carcinoma (ccRCC), 2024
Afiliaciones ( 1 en total )
● Bradford Hill Clin Ctr
Burotto, M. Autor ID: 8328135 ver autor
Articulos ( 1 en total )
● Subcutaneous nivolumab (NIVO SC) vs intravenous nivolumab (NIVO IV) in patients (pts) with previously treated advanced or metastatic clear cell renal cell carcinoma (ccRCC): Updated efficacy and safety results from CheckMate 67T, 2024
Afiliaciones ( 1 en total )
● Ctr Invest Clin Bradford Hill
Burotto, M. Autor ID: 8333254 ver autor
Articulos ( 1 en total )
● Nivolumab (NIVO) plus relatlimab with platinum-doublet chemotherapy (PDCT) vs NIVO plus PDCT as first-line (1L) treatment (tx) for stage IV or recurrent NSCLC: Results from the randomized phase II RELATIVITY-104 study, 2024
Afiliaciones ( 1 en total )
● Bradford Hill Ctr Invest Clin
ÁREA DE TRABAJO
FIRMA SELECCIONADA COMO BASE
FIRMAS SELECCIONADAS PARA AGRUPAR